Fred Cohen
Angel Investor @ Monograph Capital
San Francisco Bay Area, United States
Fred Cohen is a Series A investor at Monograph Capital in San Francisco Bay Area focused on Biotechnology and Therapeutics. Fred Cohen - Co-Founder & Sr. Managing Director @ Vida Ventures
- Total investments:
- 13
- Last investment:
- Lead investor:
- 31%
Last updated:
For AI agents: llms.txt
Industries Fred Cohen invests in
Stages Fred Cohen invests in
Countries Fred Cohen invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 7 (54%)
- Therapeutics 5 (38%)
- Health Care 4 (31%)
- Medical 3 (23%)
- Life Science 2 (15%)
Stage
- Series A 4 (31%)
- Series B 2 (15%)
- Series C 2 (15%)
- Series D 1 (8%)
- Series E 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Ollin Biosciences operates as a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening diseases. | $330M / Series B / Jun 24, 2026 | ||
| ProLynx is a biotechnology company that develops proprietary drug-delivery technologies designed to extend the half-life of therapeutic molecules, including peptides, proteins, and small molecules, so they maintain effective levels in the body for controlled periods. The company’s core platform uses β-eliminative linkers that are programmed torelease native drugs from macromolecular carriers (such as circulating polymers or hydrogel microspheres) at predictable rates, enabling sustained release over weeks to months. ProLynx applies this technology to create long-acting therapeutic candidates and partners with pharmaceutical firms and academic researchers to design and test novel drug conjugates. Its pipeline includes extended-duration therapies for metabolic and obesity indications, with a focus on formulations engineered for monthly or quarterly dosing schedules. | $70M / Series A / Dec 11, 2025 | ||
| Ollin Biosciences operates as a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening diseases. | $100M / Series A / Sep 17, 2025 | ||
| Human Immunology Biosciences is a biotechnology company that focuses on developing therapies for immune-mediated diseases. The company's lead product, felzartamab, is a fully human anti-CD38 monoclonal antibody that has been shown in clinical studies to deplete CD38+ cells that include plasma cells and natural killer, or NK, cells which mayallow for applications that improve clinical outcomes in a broad range of immune-mediated diseases. | $120M / Series A / Nov 01, 2022 | ||
| KYVERNA is pioneering a new class of treatments and potential cures for serious autoimmune diseases. Their therapeutic platform combines advanced T cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the root cause of inflammatory diseases. | $85M / Series B / Jan 26, 2022 | ||
| Allogene Therapeutics is a clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing andadvanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies. | $411.8M / Series A / Apr 19, 2018 | ||
| Roka Bioscience is dedicated to developing rapid, highly accurate molecular assays and instrument systems for the Food Safety Industry. Its newly released Atlas System represents a new tier of molecular rapid pathogen testing, offering automation and technology that bring true walk-away convenience and workflow advantages to the laboratory.Rokais focused on creating novel testing solutions that help manufacturers mitigate risks, protect their brands, and meet the increasing testing demands now and for years to come. | $47.5M / Series D / Jan 08, 2012 | ||
| CareDx is a molecular diagnostics company based in Brisbane, CA, USA. XDx applies modern genomics technologies to the development of molecular diagnostic assays that translate a patient's immune status into clinically actionable information. XDx has one marketed product, AlloMap Molecular Expression Testing, and other products underdevelopment. The proprietary molecular expression technology used by XDx to develop AlloMap testing for heart transplant patient management may be applicable to the post-transplant management of recipients of other organs. The application of gene expression testing to other diseases that involve the activity of the immune system, such as autoimmune and chronic inflammatory diseases, is also being explored. | $14.4M / Series G / Aug 05, 2009 | ||
| CareDx is a molecular diagnostics company based in Brisbane, CA, USA. XDx applies modern genomics technologies to the development of molecular diagnostic assays that translate a patient's immune status into clinically actionable information. XDx has one marketed product, AlloMap Molecular Expression Testing, and other products underdevelopment. The proprietary molecular expression technology used by XDx to develop AlloMap testing for heart transplant patient management may be applicable to the post-transplant management of recipients of other organs. The application of gene expression testing to other diseases that involve the activity of the immune system, such as autoimmune and chronic inflammatory diseases, is also being explored. | $26.5M / Series E / Dec 01, 2005 | ||
| FivePrime is discovering and developing novel therapeutic proteins and antibodies by systematically screening all relevant proteins in the human body to find the best protein for treatment of a given clinical indication. FivePrime’s ProScreen Engine enables the rapid production and screening of all therapeuticallyrelevant proteins in medically-focused assays at the highest quality standards in the industry. This powerful approach is the polar opposite of the industry’s traditional “one protein at a time”. The ProScreen Engine comprises the definitive protein collection and screening process for biologics discovery and is unprecedented in its efficiency, quality, and scale. In addition to DBL Investors, investors include Domain Associates, Versant Ventures, Kleiner Perkins Caufield and Byers, Texas Pacific Group, HealthCap, and Advanced Technology Ventures. | $45M / Feb 08, 2005 | ||
| See all 13 investments → | |||
Co-Investors
About Monograph Capital
Monograph Capital is a life sciences venture firm. We find and fund groundbreaking life sciences companies to transform promising science into real, life-changing treatments for people across the world.
Monograph Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Charles Conn
Co-founder
|
|||
Tim Funnell
Partner
|
|||
Bonnie van Wilgenburg
Principal
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Fred Cohen invest in?
Fred Cohen invests primarily in Biotechnology, Therapeutics and Health Care startups, most often at Series A and Series B stage. Most of the 13 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Fred Cohen?
Public channels for Fred Cohen include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Fred Cohen last invest?
The most recent investment recorded for Fred Cohen closed in Jun 2026. Shizune tracks 13 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
